Primecap Management Co. CA Has $24.98 Million Stock Position in Repligen Corporation $RGEN

Primecap Management Co. CA raised its stake in Repligen Corporation (NASDAQ:RGEN) by 35.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 186,868 shares of the biotechnology company’s stock after acquiring an additional 48,590 shares during the quarter. Primecap Management Co. CA owned about 0.33% of Repligen worth $24,979,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. Hantz Financial Services Inc. increased its stake in shares of Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 293 shares during the period. CWM LLC boosted its stake in Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares during the period. Center for Financial Planning Inc. grew its holdings in Repligen by 34.2% in the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 126 shares in the last quarter. Trust Co. of Vermont bought a new position in Repligen during the 3rd quarter worth $67,000. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after buying an additional 495 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on RGEN shares. Wells Fargo & Company lowered their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research report on Wednesday. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a report on Wednesday. Barclays dropped their price target on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, UBS Group dropped their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $128.73 on Friday. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $175.77. The stock has a market capitalization of $7.25 billion, a price-to-earnings ratio of 151.45, a price-to-earnings-growth ratio of 2.54 and a beta of 1.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.14. The company’s 50 day simple moving average is $154.18 and its 200 day simple moving average is $146.80.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. During the same quarter last year, the business posted $0.44 EPS. The company’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, research analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director owned 91,821 shares in the company, valued at $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.